Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
N-acetyl-L-cysteine inhibits marble-burying behavior in mice.
Egashira N, Shirakawa A, Abe M, Niki T, Mishima K, Iwasaki K, Oishi R, Fujiwara M. Egashira N, et al. Among authors: abe m. J Pharmacol Sci. 2012;119(1):97-101. doi: 10.1254/jphs.11228sc. Epub 2012 Apr 18. J Pharmacol Sci. 2012. PMID: 22510519 Free article.
Calcium-channel antagonists inhibit marble-burying behavior in mice.
Egashira N, Okuno R, Abe M, Matsushita M, Mishima K, Iwasaki K, Oishi R, Nishimura R, Matsumoto Y, Fujiwara M. Egashira N, et al. Among authors: abe m. J Pharmacol Sci. 2008 Sep;108(1):140-3. doi: 10.1254/jphs.08160sc. Epub 2008 Aug 30. J Pharmacol Sci. 2008. PMID: 18758134 Free article.
Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.
Egashira N, Iwasaki K, Ishibashi A, Hayakawa K, Okuno R, Abe M, Uchida N, Mishima K, Takasaki K, Nishimura R, Oishi R, Fujiwara M. Egashira N, et al. Among authors: abe m. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1516-20. doi: 10.1016/j.pnpbp.2008.05.010. Epub 2008 May 20. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18558456
A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment.
Sezai A, Abe M, Maruyama T, Taoka M, Sekino H, Tanaka M. Sezai A, et al. Among authors: abe m. J Clin Med. 2024 May 8;13(10):2764. doi: 10.3390/jcm13102764. J Clin Med. 2024. PMID: 38792306 Free PMC article.
6,076 results